title: The clinical significance of massive intratumoral lymphocytosis in squamous cell carcinoma of the anus.
abstract: A recent report indicates that patients with squamous cell carcinoma of the anal canal (SCCAC) and intraepithelial lymphocytes have a poor prognosis. Against that background, histological sections from 277 consecutive SCCACs were reviewed searching for cases with massive tumor-infiltrating lymphocytes (TILs; >/= 50 lymphocytes /100 tumor cells). Of the 277 SCCACs, 8 (3%) had massive TILs. These 8 patients (all females) had both more advanced clinical stage than the remaining 269 control SCCAC patients. Follow-up studies revealed that the 8 patients with SCCACs having massive TILs had a much better 15 years survival rate than control SCCAC patients. It is concluded that despite SCCAC patients with massive TILs had a more advanced clinical stage than SCCAC controls, SCCAC with massive TILs patients had a longer survival rate (with no deaths after 5 years) than control cases. The search via proteomic methodology for the lymphocyte-attracting tumor protein might bring forward a novel co-adjuvant therapy, capable to increase prolonged survival time in patients having SCCAC without massive TILs.
authors.affiliation: Department of Pathology, Karolinska University Hospital 17176, Stockholm. Carlos.Rubio@ki.se
authors.forename: Carlos A
authors.initials: CA
authors.lastname: Rubio
authors.forename: Per J
authors.initials: PJ
authors.lastname: Nilsson
authors.forename: Fredrik
authors.initials: F
authors.lastname: Petersson
authors.forename: Ander
authors.initials: A
authors.lastname: Höög
authors.forename: Harald
authors.initials: H
authors.lastname: Blegen
authors.forename: Runjan
authors.initials: R
authors.lastname: Chetty
references.citation: Cancer Res. 2001 May 15;61(10):3932-6
references.pmid: 11358808
references.citation: Ann Oncol. 2005 Jun;16(6):893-8
references.pmid: 15821121
references.citation: Am J Surg Pathol. 2005 Dec;29(12):1668-72
references.pmid: 16327441
references.citation: Dan Med Bull. 2002 Aug;49(3):194-209
references.pmid: 12238281
references.citation: Mod Pathol. 1992 Mar;5(2):191-6
references.pmid: 1574497
references.citation: Int Immunol. 1995 Jul;7(7):1135-45
references.pmid: 8527411
references.citation: Cancer. 2004 Jul 15;101(2):270-80
references.pmid: 15241823
references.citation: Cancer Res. 1999 Feb 1;59(3):753-7
references.pmid: 9973228
references.citation: Cancer Res. 1999 Apr 1;59(7):1531-8
references.pmid: 10197625
references.citation: Am J Epidemiol. 2003 Jun 1;157(11):966-72
references.pmid: 12777359
references.citation: Cancer Res. 1997 Jun 1;57(11):2216-22
references.pmid: 9187124
references.citation: Int J Colorectal Dis. 2000 Nov;15(5-6):282-90
references.pmid: 11151431
references.citation: Am J Pathol. 2001 Feb;158(2):527-35
references.pmid: 11159189
references.citation: Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3355-60
references.pmid: 16740757
references.citation: Int J Colorectal Dis. 2006 Mar;21(2):135-42
references.pmid: 15864603
references.citation: Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):92-102
references.pmid: 15629599
references.citation: Clin Cancer Res. 2005 Oct 15;11(20):7322-7
references.pmid: 16243803
references.citation: Virchows Arch. 2000 Mar;436(3):229-33
references.pmid: 10782881